Skip to main content
PMC home page
Heart logoLink to Heart
. 2005 May;91(Suppl 2):ii7–ii13. doi: 10.1136/hrt.2005.062026

Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction

J Cleland, A Torabi, N Khan
PMCID: PMC1876349  PMID: 15831613

Abstract

Robust epidemiological data on the incidence of myocardial infarction (MI) are hard to find, but synthesis of data from a number of sources indicates that the average hospital in the UK should admit about two patients with a first MI and one recurrent MI per 1000 population per year. Possibly the most relevant data on the incidence, prevalence, and persistence of post-MI heart failure can be derived from the TRACE study. Most patients will develop heart failure or major left ventricular systolic dysfunction (LVSD) at some time after an MI, most commonly during the index admission. In up to 20% of cases this will be transient, but such patients still have a poor prognosis. There is likely to be around one patient discharged per thousand population per year with heart failure or major LVSD after an acute MI. It is important to organise care structures to ensure that patients with post-MI heart failure and LVSD are identified and managed appropriately.

Full Text

The Full Text of this article is available as a PDF (94.5 KB).

Figure 1.

Figure 1

Open in a new tab

 Median life expectancy after a myocardial infarction complicated by major left ventricular systolic dysfunction in the TRACE study.48 Comparison between the effect of placebo and trandolapril. ACE, angiotensin converting enzyme; CHF, congestive heart failure; HBP, high blood pressure.

Figure 2.

Figure 2

Open in a new tab

 Proportion of patients with heart failure and left ventricular systolic dysfunction within the first few days after a myocardial infarction in the TRACE study.27

Figure 3.

Figure 3

Open in a new tab

 Proportion of patients with left ventricular systolic dysfunction, transient or persistent heart failure (HF) and their outcome in the TRACE study.28 WMI, wall motion index.

Figure 4.

Figure 4

Open in a new tab

 Pharmacological treatment after ST segment elevation (STE), non-ST segment elevation (Non-STE), and "ECG indeterminant" (Uncertain) myocardial infarction in the EuroHeart acute coronary syndrome survey. ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; BB, ß blocker.

Figure 5.

Figure 5

Open in a new tab

 Pharmacological treatment after a myocardial infarction complicated by heart failure and/or left ventricular systolic dysfunction in three contemporary clinical trials.41,45–47 In VALIANT and OPTIMAAL patients already taking ACE inhibitors or angiotensin receptor blockers were excluded. ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; BB, ß blocker; HF, heart failure; LVSD, left ventricular systolic dysfunction.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronow W. S., Ahn C., Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol. 1997 Jul 15;80(2):207–209. doi: 10.1016/s0002-9149(97)00320-2. [DOI] [PubMed] [Google Scholar]
  2. Aronow W. S., Ahn C., Kronzon I. Prognosis of congestive heart failure in elderly patients with normal versus abnormal left ventricular systolic function associated with coronary artery disease. Am J Cardiol. 1990 Nov 15;66(17):1257–1259. doi: 10.1016/0002-9149(90)91112-j. [DOI] [PubMed] [Google Scholar]
  3. Braunstein Joel B., Anderson Gerard F., Gerstenblith Gary, Weller Wendy, Niefeld Marlene, Herbert Robert, Wu Albert W. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003 Oct 1;42(7):1226–1233. doi: 10.1016/s0735-1097(03)00947-1. [DOI] [PubMed] [Google Scholar]
  4. Brieger David, Eagle Kim A., Goodman Shaun G., Steg P. Gabriel, Budaj Andrzej, White Kami, Montalescot Gilles, GRACE Investigators Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest. 2004 Aug;126(2):461–469. doi: 10.1378/chest.126.2.461. [DOI] [PubMed] [Google Scholar]
  5. Caruana L., Petrie M. C., Davie A. P., McMurray J. J. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. BMJ. 2000 Jul 22;321(7255):215–218. doi: 10.1136/bmj.321.7255.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Christian T. F., Gitter M. J., Miller T. D., Gibbons R. J. Prospective identification of myocardial stunning using technetium-99m sestamibi-based measurements of infarct size. J Am Coll Cardiol. 1997 Dec;30(7):1633–1640. doi: 10.1016/s0735-1097(97)00409-9. [DOI] [PubMed] [Google Scholar]
  7. Cleland J. G. Anticoagulant and antiplatelet therapy in heart failure. Curr Opin Cardiol. 1997 May;12(3):276–287. doi: 10.1097/00001573-199705000-00009. [DOI] [PubMed] [Google Scholar]
  8. Cleland J. G., Massie B. M., Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail. 1999 Mar;1(1):41–45. doi: 10.1016/S1388-9842(99)00009-4. [DOI] [PubMed] [Google Scholar]
  9. Cleland John G. F., Huan Loh P., Freemantle Nick, Clark Andrew L., Coletta Alison P. Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION, and the HF-ACTION trial. Eur J Heart Fail. 2004 Oct;6(6):787–791. doi: 10.1016/j.ejheart.2004.09.001. [DOI] [PubMed] [Google Scholar]
  10. Cleland John G. F. Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis. 2002 Jan-Feb;44(4):275–292. doi: 10.1053/pcad.2002.31597. [DOI] [PubMed] [Google Scholar]
  11. Dargie H. J. Design and methodology of the CAPRICORN trial - a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2000 Sep;2(3):325–332. doi: 10.1016/s1388-9842(00)00098-2. [DOI] [PubMed] [Google Scholar]
  12. Dickstein Kenneth, Kjekshus John, OPTIMAAL Steering Committee of the OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002 Sep 7;360(9335):752–760. doi: 10.1016/s0140-6736(02)09895-1. [DOI] [PubMed] [Google Scholar]
  13. Dorsch M. F., Lawrance R. A., Sapsford R. J., Durham N., Oldham J., Greenwood D. C., Jackson B. M., Morrell C., Robinson M. B., Hall A. S. Poor prognosis of patients presenting with symptomatic myocardial infarction but without chest pain. Heart. 2001 Nov;86(5):494–498. doi: 10.1136/heart.86.5.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gandhi S. K., Powers J. C., Nomeir A. M., Fowle K., Kitzman D. W., Rankin K. M., Little W. C. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001 Jan 4;344(1):17–22. doi: 10.1056/NEJM200101043440103. [DOI] [PubMed] [Google Scholar]
  15. Guidry U. C., Evans J. C., Larson M. G., Wilson P. W., Murabito J. M., Levy D. Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. Circulation. 1999 Nov 16;100(20):2054–2059. doi: 10.1161/01.cir.100.20.2054. [DOI] [PubMed] [Google Scholar]
  16. Hasdai D., Behar S., Wallentin L., Danchin N., Gitt A. K., Boersma E., Fioretti P. M., Simoons M. L., Battler A. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J. 2002 Aug;23(15):1190–1201. doi: 10.1053/euhj.2002.3193. [DOI] [PubMed] [Google Scholar]
  17. Hellermann Jens P., Goraya Tauqir Y., Jacobsen Steven J., Weston Susan A., Reeder Guy S., Gersh Bernard J., Redfield Margaret M., Rodeheffer Richard J., Yawn Barbara P., Roger Véronique L. Incidence of heart failure after myocardial infarction: is it changing over time? Am J Epidemiol. 2003 Jun 15;157(12):1101–1107. doi: 10.1093/aje/kwg078. [DOI] [PubMed] [Google Scholar]
  18. Hellermann Jens P., Jacobsen Steven J., Gersh Bernard J., Rodeheffer Richard J., Reeder Guy S., Roger Véronique L. Heart failure after myocardial infarction: a review. Am J Med. 2002 Sep;113(4):324–330. doi: 10.1016/s0002-9343(02)01185-3. [DOI] [PubMed] [Google Scholar]
  19. Hellermann Jens P., Jacobsen Steven J., Redfield Margaret M., Reeder Guy S., Weston Susan A., Roger Véronique L. Heart failure after myocardial infarction: clinical presentation and survival. Eur J Heart Fail. 2005 Jan;7(1):119–125. doi: 10.1016/j.ejheart.2004.04.011. [DOI] [PubMed] [Google Scholar]
  20. Hellermann Jens P., Jacobsen Steven J., Reeder Guy S., Lopez-Jimenez Francisco, Weston Susan A., Roger Véronique L. Heart failure after myocardial infarction: prevalence of preserved left ventricular systolic function in the community. Am Heart J. 2003 Apr;145(4):742–748. doi: 10.1067/mhj.2003.187. [DOI] [PubMed] [Google Scholar]
  21. Houghton T., Freemantle N., Cleland J. G. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. Eur J Heart Fail. 2000 Sep;2(3):333–340. doi: 10.1016/s1388-9842(00)00100-8. [DOI] [PubMed] [Google Scholar]
  22. James Stefan K., Lindahl Bertil, Siegbahn Agneta, Stridsberg Mats, Venge Per, Armstrong Paul, Barnathan Elliot S., Califf Robert, Topol Eric J., Simoons Maarten L. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003 Jul 7;108(3):275–281. doi: 10.1161/01.CIR.0000079170.10579.DC. [DOI] [PubMed] [Google Scholar]
  23. Kannel W. B., Abbott R. D. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med. 1984 Nov 1;311(18):1144–1147. doi: 10.1056/NEJM198411013111802. [DOI] [PubMed] [Google Scholar]
  24. Krum Henry, McMurray John J. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol. 2002 May 15;39(10):1567–1573. doi: 10.1016/s0735-1097(02)01827-2. [DOI] [PubMed] [Google Scholar]
  25. Køber L., Torp-Pedersen C., Carlsen J. E., Bagger H., Eliasen P., Lyngborg K., Videbaek J., Cole D. S., Auclert L., Pauly N. C. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995 Dec 21;333(25):1670–1676. doi: 10.1056/NEJM199512213332503. [DOI] [PubMed] [Google Scholar]
  26. Køber L., Torp-Pedersen C. Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. Am J Cardiol. 1995 Jul 1;76(1):1–5. doi: 10.1016/s0002-9149(99)80791-7. [DOI] [PubMed] [Google Scholar]
  27. Køber L., Torp-Pedersen C., Jørgensen S., Eliasen P., Camm A. J. Changes in absolute and relative importance in the prognostic value of left ventricular systolic function and congestive heart failure after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Am J Cardiol. 1998 Jun 1;81(11):1292–1297. doi: 10.1016/s0002-9149(98)00158-1. [DOI] [PubMed] [Google Scholar]
  28. Køber L., Torp-Pedersen C., Pedersen O. D., Høiberg S., Camm A. J. Importance of congestive heart failure and interaction of congestive heart failure and left ventricular systolic function on prognosis in patients with acute myocardial infarction. Am J Cardiol. 1996 Nov 15;78(10):1124–1128. doi: 10.1016/s0002-9149(96)90064-8. [DOI] [PubMed] [Google Scholar]
  29. McKenna Charles J., Forfar J. Colin. Was it a heart attack? BMJ. 2002 Feb 16;324(7334):377–378. doi: 10.1136/bmj.324.7334.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Mosterd A., Deckers J. W., Hoes A. W., Nederpel A., Smeets A., Linker D. T., Grobbee D. E. Classification of heart failure in population based research: an assessment of six heart failure scores. Eur J Epidemiol. 1997 Jul;13(5):491–502. doi: 10.1023/a:1007383914444. [DOI] [PubMed] [Google Scholar]
  31. Murphy N. F., MacIntyre K., Capewell S., Stewart S., Pell J., Chalmers J., Redpath A., Frame S., Boyd J., McMurray J. J. V. Hospital discharge rates for suspected acute coronary syndromes between 1990 and 2000: population based analysis. BMJ. 2004 May 21;328(7453):1413–1414. doi: 10.1136/bmj.38111.650741.F7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Møller Jacob Eifer, Brendorp Bente, Ottesen Michael, Køber Lars, Egstrup Kenneth, Poulsen Steen Hvitfelt, Torp-Pedersen Christian, Bucindolol Evaluation in Acute Myocardial Infarction Trail Group Congestive heart failure with preserved left ventricular systolic function after acute myocardial infarction: clinical and prognostic implications. Eur J Heart Fail. 2003 Dec;5(6):811–819. doi: 10.1016/s1388-9842(03)00159-4. [DOI] [PubMed] [Google Scholar]
  33. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  34. Pfeffer Marc A., McMurray John J. V., Velazquez Eric J., Rouleau Jean-Lucien, Køber Lars, Maggioni Aldo P., Solomon Scott D., Swedberg Karl, Van de Werf Frans, White Harvey. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 Nov 10;349(20):1893–1906. doi: 10.1056/NEJMoa032292. [DOI] [PubMed] [Google Scholar]
  35. Pitt Bertram, Remme Willem, Zannad Faiez, Neaton James, Martinez Felipe, Roniker Barbara, Bittman Richard, Hurley Steve, Kleiman Jay, Gatlin Marjorie. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Mar 31;348(14):1309–1321. doi: 10.1056/NEJMoa030207. [DOI] [PubMed] [Google Scholar]
  36. Richards A. M., Nicholls M. G., Yandle T. G., Ikram H., Espiner E. A., Turner J. G., Buttimore R. C., Lainchbury J. G., Elliott J. M., Frampton C. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart. 1999 Feb;81(2):114–120. doi: 10.1136/hrt.81.2.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Richards A. Mark, Nicholls M. Gary, Espiner Eric A., Lainchbury John G., Troughton Richard W., Elliott John, Frampton Christopher, Turner John, Crozier Ian G., Yandle Timothy G. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003 May 27;107(22):2786–2792. doi: 10.1161/01.CIR.0000070953.76250.B9. [DOI] [PubMed] [Google Scholar]
  38. Roger Véronique L., Weston Susan A., Redfield Margaret M., Hellermann-Homan Jens P., Killian Jill, Yawn Barbara P., Jacobsen Steven J. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004 Jul 21;292(3):344–350. doi: 10.1001/jama.292.3.344. [DOI] [PubMed] [Google Scholar]
  39. Rosamond W. D., Chambless L. E., Folsom A. R., Cooper L. S., Conwill D. E., Clegg L., Wang C. H., Heiss G. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 1998 Sep 24;339(13):861–867. doi: 10.1056/NEJM199809243391301. [DOI] [PubMed] [Google Scholar]
  40. Rosamond W. D., Folsom A. R., Chambless L. E., Wang C. H., ARIC Investigators. Atherosclerosis Risk in Communities Coronary heart disease trends in four United States communities. The Atherosclerosis Risk in Communities (ARIC) study 1987-1996. Int J Epidemiol. 2001 Oct;30 (Suppl 1):S17–S22. doi: 10.1093/ije/30.suppl_1.s17. [DOI] [PubMed] [Google Scholar]
  41. Solomon S. D., Glynn R. J., Greaves S., Ajani U., Rouleau J. L., Menapace F., Arnold J. M., Hennekens C., Pfeffer M. A. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med. 2001 Mar 20;134(6):451–458. doi: 10.7326/0003-4819-134-6-200103200-00009. [DOI] [PubMed] [Google Scholar]
  42. Spencer Frederick A., Meyer Theo E., Gore Joel M., Goldberg Robert J. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction. Circulation. 2002 Jun 4;105(22):2605–2610. doi: 10.1161/01.cir.0000017861.00991.2f. [DOI] [PubMed] [Google Scholar]
  43. St John Sutton M., Pfeffer M. A., Moye L., Plappert T., Rouleau J. L., Lamas G., Rouleau J., Parker J. O., Arnold M. O., Sussex B. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation. 1997 Nov 18;96(10):3294–3299. doi: 10.1161/01.cir.96.10.3294. [DOI] [PubMed] [Google Scholar]
  44. Torp-Pedersen C., Køber L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet. 1999 Jul 3;354(9172):9–12. doi: 10.1016/s0140-6736(98)09374-x. [DOI] [PubMed] [Google Scholar]
  45. Tunstall-Pedoe H., Kuulasmaa K., Mähönen M., Tolonen H., Ruokokoski E., Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet. 1999 May 8;353(9164):1547–1557. doi: 10.1016/s0140-6736(99)04021-0. [DOI] [PubMed] [Google Scholar]
  46. Velazquez Eric J., Pfeffer Marc A., McMurray John V., Maggioni Aldo P., Rouleau Jean Lucien, Van de Werf Frans, Kober Lars, White Harvey D., Swedberg Karl, Leimberger Jeffrey D. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail. 2003 Aug;5(4):537–544. doi: 10.1016/s1388-9842(03)00112-0. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES